Towards the Crystal Structure Determination of Muscarinic Acetylcholine Receptors

Part of the Neuromethods book series (NM, volume 107)

Abstract

G protein-coupled receptors (GPCRs) constitute the largest family of receptors encoded by the human genome. Activation and inhibition of GPCRs under the physiological and pathophysiological conditions is largely mediated by chemical ligands (agonists and antagonists) that bind to the orthosteric binding pocket. Orthosteric ligands are, however, often nonspecific, binding to more than one GPCR subtype. In contrast to orthosteric agonists and antagonists, allosteric ligands do not directly compete with hormones and neurotransmitters for binding to the orthosteric binding pocket. Furthermore, allosteric ligands typically occupy structurally diverse regions of receptors and therefore are more selective for specific GPCRs, regulating receptor function in the more subtle ways by either enhancing or diminishing responses to natural ligands such as hormones or neurotransmitters. Recent X-ray crystallographic studies have provided detailed structural information regarding the nature of the orthosteric muscarinic binding site and an outer receptor cavity that can bind allosteric drugs. These new findings may guide the development of selective muscarinic receptor. The procedures involved in the production, purification, and crystallization of GPCRs are introduced here and facilitate a greater understanding of the structural basis of GPCR function.

Key words

G-protein coupled receptor X-ray crystal structure analysis Muscarinic acetylcholine receptor Antagonist Agonist Orthosteric binding site Allosteric binding site 

Notes

Acknowledgments

This work was supported by the Exploratory Research for Advanced Technology (ERATO) program of the Japan Science and Technology Agency (JST) (to T.K.), by the Toray Science Foundation (to T.K.), by Takeda Science Foundation (to T.K., R.S., and H.A.), by Ichiro Kanehara Foundation (to T.K.), by The Sumitomo Foundation (to T.K.), by the Core Research for Evolutional Science and Technology (CREST) program of the JST (to T.K.), and by the Platform for Drug Discovery, Informatics, and Structural Life Science from the Ministry of Education, Culture, Sports, Science and Technology, Japan (to T.K.).

Supplementary material

323171_1_En_1_MOESM1_ESM.pptx (5.6 mb)
Supplementary Fig. 1 This slide shows that structure of orthosteric domains similar among M1–M5 receptor subtypes. Asp103 conserved among all amine receptor has made a salt bridge with the amine of QNB, muscarinic receptor antagonist. Asn404 conserved among all muscarinic receptors has made hydrogen bonds with hydroxyl and carbonyl of QNB. There are 14 amino acids around QNB. Except Phe181, 13 amino acids of receptor are conserved among M1–M5 receptor subtypes. To develop the subtype specific ligand, we have to target the allosteric domain, not the orthosteric domain (PPTX 5750 kb)

References

  1. 1.
    Hopkins AL, Groom CR (2002) The druggable genome. Nat Rev Drug Discov 1(9):727–730PubMedCrossRefGoogle Scholar
  2. 2.
    Klabunde T, Hessler G (2002) Drug design strategies for targeting G-protein-coupled receptors. Chembiochem 3:455–459CrossRefGoogle Scholar
  3. 3.
    Bonner TI, Buckley NJ, Young AC, Brann MR (1987) Identification of a family of muscarinic acetylcholine receptor genes. Science 237(4814):527–532PubMedCrossRefGoogle Scholar
  4. 4.
    Peralta EG, Winslow JW, Peterson GL, Smith DH (1987) Primary structure and biochemical property of an M2 muscarinic receptor. Science 236(4801):600–605PubMedCrossRefGoogle Scholar
  5. 5.
    Bonner TI, Young AC, Brann MR, Buckley NJ (1988) Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes. Neuron 1(5):403–410PubMedCrossRefGoogle Scholar
  6. 6.
    Bonner TI (1989) The molecular basis of muscarinic receptor diversity. Trends Neurosci 12(4):148–151PubMedCrossRefGoogle Scholar
  7. 7.
    Bonner TI (1989) New subtypes of muscarinic acetylcholine receptors. Trends Pharmacol Sci Suppl 11:5Google Scholar
  8. 8.
    Wess J, Bonner TI, Dorje F, Brann MR (1990) Delineation of muscarinic receptor domains conferring selectivity of coupling to guanine nucleotide-binding proteins and second messengers. Mol Pharmacol 38(4):517–523PubMedGoogle Scholar
  9. 9.
    Wess J, Bonner TI, Brann MR (1990) Chimeric m2/m3 muscarinic receptors: role of carboxyl terminal receptor domains in selectivity of ligand binding and coupling to phosphoinositide hydrolysis. Mol Pharmacol 38(6):872–877PubMedGoogle Scholar
  10. 10.
    Wess J, Liu J, Blin N et al (1997) Structural basis of receptor/G protein coupling selectivity studied with muscarinic receptors as model systems. Life Sci 60(13–14):1007–1014PubMedCrossRefGoogle Scholar
  11. 11.
    Haga K, Kruse AC, Asada H et al (2012) Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist. Nature 482(7386):547–551PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Kruse AC, Hu J, Pan AC et al (2012) Structure and dynamics of the M3 muscarinic acetylcholine receptor. Nature 482(7386):547–551PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Alkhalfioui F, Magnin T, Wagner R (2009) From purified GPCRs to drug discovery: the promise of protein-based methodologies. Curr Opin Pharmacol 9(5):629–635PubMedCrossRefGoogle Scholar
  14. 14.
    Furukawa H, Haga T (2000) Expression of functional M2 muscarinic acetylcholine receptor in Escherichia coli. J Biochem 127(1):151–161PubMedCrossRefGoogle Scholar
  15. 15.
    Ichiyama S, Oka Y, Haga K et al (2006) The structure of the third intracellular loop of the muscarinic acetylcholine receptor M2 subtype. FEBS Lett 580(1):23–26PubMedCrossRefGoogle Scholar
  16. 16.
    Yurugi-Kobayashi T, Asada H, Shiroishi M et al (2009) Comparison of functional non-glycosylated GPCRs expression in Pichia pastoris. Biochem Biophys Res Commun 380(2):271–276PubMedCrossRefGoogle Scholar
  17. 17.
    Hayashi MK, Haga T (1996) Purification and functional reconstitution with GTP-binding regulatory proteins of hexahistidine-tagged muscarinic acetylcholine receptors (m2 subtype). J Biochem 120(6):1232–1238PubMedCrossRefGoogle Scholar
  18. 18.
    Asada H, Uemura T, Yurugi-Kobayashi T et al (2011) Evaluation of the Pichia pastoris expression system for the production of GPCRs for structural analysis. Microb Cell Fact 10:24PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Kameyama K, Haga K, Haga T et al (1994) Activation of a GTP-binding protein and a GTP-binding-protein-coupled receptor kinase (β-adrenergic-receptor kinase-1) by a muscarinic receptor m2 mutant lacking phosphorylation sites. Eur J Biochem 226:267–276PubMedCrossRefGoogle Scholar
  20. 20.
    Rosenbaum DM, Cherezov V, Hanson MA et al (2007) GPCR engineering yields high-resolution structural insights into β2-adrenergic receptor function. Science 318(5854):1266–1273PubMedCrossRefGoogle Scholar
  21. 21.
    Ballesteros JA, Weinstein H (1995) Integrated methods for the construction of three dimensional models and computational probing of structure function relations in G protein-coupled receptors. Methods Neurosci 25:366–428CrossRefGoogle Scholar
  22. 22.
    Scorer CA, Clare JJ, McCombie WR et al (1994) Rapid selection using G418 of high copy number transformants of Pichia pastoris for high-level foreign gene expression. Biotechnology (NY) 12(2):181–184CrossRefGoogle Scholar
  23. 23.
    Weiss HM, Haase W, Michel H et al (1998) Comparative biochemical and pharmacological characterization of the mouse 5HT5A 5-hydroxytryptamine receptor and the human beta2-adrenergic receptor produced in the methylotrophic yeast Pichia pastoris. Biochem J 330(Pt 3):1137–1147PubMedCentralPubMedGoogle Scholar
  24. 24.
    Ciccarone VC, Polayes DA, Luckow VA (1998) Generation of recombinant baculovirus DNA in E. coli using a baculovirus shuttle vector. Methods Mol Med 13:213–235PubMedGoogle Scholar
  25. 25.
    Luckow VA, Lee SC, Barry GF et al (1993) Efficient generation of infectious recombinant baculoviruses by site-specific transposon-mediated insertion of foreign genes into a baculovirus genome propagated in Escherichia coli. J Virol 67(8):4566–4579PubMedCentralPubMedGoogle Scholar
  26. 26.
    Kadwell SH, Hardwicke PI (2007) Production of baculovirus-expressed recombinant proteins in wave bioreactors. Methods Mol Biol 388:247–266PubMedCrossRefGoogle Scholar
  27. 27.
    Weber W, Weber E, Geisse S et al (2002) Optimisation of protein expression and establishment of the Wave Bioreactor for Baculovirus/insect cell culture. Cytotechnology 38(1–3):77–85PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Haga K, Haga T (1983) Affinity chromatography of the muscarinic acetylcholine receptor. J Biol Chem 258(22):13575–13579PubMedGoogle Scholar
  29. 29.
    Kruse AC, Ring AM, Manglik A et al (2013) Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature 504(7478):101–106PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Ryoji Suno
    • 1
    • 3
  • Hidetsugu Asada
    • 1
  • Takuya Kobayashi
    • 1
    • 2
    • 3
  1. 1.Department of Medical Chemistry and Cell BiologyKyoto University Graduate School of MedicineKyotoJapan
  2. 2.Japan Science and Technology Agency (JST)Core Research for Evolutional Science and Technology (CREST)KyotoJapan
  3. 3.Platform for Drug Discovery, Informatics and Structural Life ScienceKyotoJapan

Personalised recommendations